Amgen (AMGN) is trading higher on April 30, 2026 as investors react to a better-than-expected first-quarter 2026 earnings update that hit markets late April 29, ahead of the company’s scheduled post-close reporting window for April 30. The move reflects renewed confidence in near-term execution and the durability of Amgen’s large, cash-generating portfolio. (amgen.com)

Amgen’s quarter featured revenue of $8.3 billion, up 12% year over year, alongside adjusted EPS of $5.15, which topped consensus estimates. Investors also appear encouraged that management reaffirmed full-year 2026 guidance, reducing fears that pricing pressure and portfolio transitions would force an outlook reset. (ad-hoc-news.de)

The quarter’s growth was framed around continued demand in major franchises, with attention on established blockbusters such as Enbrel and Prolia as meaningful contributors. With the U.S. representing the majority of sales, a firm U.S. demand backdrop has been a key pillar of the upside narrative in today’s trade. (ad-hoc-news.de)

With Amgen scheduled to discuss results on its first-quarter 2026 earnings webcast on April 30 after the U.S. market close, investors will be listening for details on drivers behind the beat, expense discipline, and any shifts in 2026 assumptions. Updates on late-stage pipeline timelines and commercialization plans are likely to be the next catalysts for sentiment after today’s initial post-results repricing. (amgen.com)